SEARCH

SEARCH BY CITATION

References

  • Bein K and Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. J Biol Chem, 275, 3216732173.
  • Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808812.
  • Bergers G et al. (2000) Matrix metalloproteinase-9 triggers the angio genic switch during carcinogenesis. Nature Cell Biol, 2, 737744.
  • Bolontrade MF, Stern MC, Binder RL, Zenklusen JC, Gimenez-Conti IB and Conti CJ (1998) Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis, 19, 21072113.
  • Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR and Yang Z (2000) Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol, 19, 557568.
  • Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM and Dvorak HF (1997) Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS, 79, 233269.
  • Campbell SC, Volpert OV, Ivanovich M and Bouck NP (1998) Molecular mediators of angiogenesis in bladder cancer. Cancer Res, 58, 12981304.
  • Caughey GH, Viro NF, Calonico LD, McDonald DM, Lazarus SC and Gold WM (1988) Chymase and tryptase in dog mastocytoma cells: asynchronous expression as revealed by enzyme cytochemical staining. J Histochem Cytochem, 36, 10531060.
  • Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH and Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev, 13, 13821397.
  • Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA and Bouck NP (1997) CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol, 138, 707717.
  • Dejana E, Corada M and Lampugnani MG (1995) Endothelial cell-to-cell junctions. FASEB J, 9, 910918.
  • Detmar M et al. (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol, 111, 16.
  • DiGiovanni J (1992) Multistage carcinogenesis in mouse skin. Pharmacol Ther, 54, 63128.
  • Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G and Moses MA (2000) Matrix metallo proteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA, 97, 38843889.
  • Ferrara N (1995) The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat, 36, 127137.
  • Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol, 3, 6571.
  • Greenhalgh DA et al. (1993) Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia. Oncogene, 8, 21452157.
  • Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353364.
  • Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell, 100, 5770.
  • Hanahan D, Christofori G, Naik P and Arbeit J (1996) Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls and prospects for preclinical therapeutic models. Eur J Cancer, 32A, 23862393.
  • Holmgren L, O'Reilly MS and Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med, 1, 149153.
  • Huitfeldt HS, Heyden A, Clausen OP, Thrane EV, Roop D and Yuspa SH (1991) Altered regulation of growth and expression of differentiation-associated keratins in benign mouse skin tumors. Carcinogenesis, 12, 20632067.
  • Iruela-Arispe ML, Bornstein P and Sage H (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA, 88, 50265030.
  • Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL and Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature Med, 6, 4148.
  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841844.
  • Kyriakides TR et al. (1998a) Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density and a bleeding diathesis. J Cell Biol, 140, 419430.
  • Kyriakides TR, Zhu YH, Yang Z and Bornstein P (1998b) The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J Histochem Cytochem, 46, 10071015.
  • Kyriakides TR, Leach KJ, Hoffman AS, Ratner BD and Bornstein P (1999a) Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci USA, 96, 44494454.
  • Kyriakides TR, Tam JW and Bornstein P (1999b) Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol, 113, 782787.
  • Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ and Jorcano JL (1996) Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res, 56, 53915396.
  • Larcher F, Murillas R, Bolontrade M, Conti CJ and Jorcano JL (1998) VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene, 17, 303311.
  • Lawler J (2000) The functions of thrombospondin-1 and -2. Curr Opin Cell Biol, 12, 634640.
  • Leder LD (1979) The chloroacetate esterase reaction. A useful means of histological diagnosis of hematological disorders from paraffin sections of skin. Am J Dermatopathol, 1, 3942.
  • Mehrel T et al. (1990) Identification of a major keratinocyte cell envelope protein, loricrin. Cell, 61, 11031112.
  • Moore RJ et al. (1999) Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med, 5, 828831.
  • Murphy-Ullrich JE, Gurusiddappa S, Frazier WA and Hook M (1993) Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J Biol Chem, 268, 2678426789.
  • O'Reilly MS et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315328.
  • O'Reilly MS et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277285.
  • Oshika Y et al. (1998) Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res, 4, 17851788.
  • Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J and Hanahan D (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA, 93, 20022007.
  • Pike SE et al. (1998) Vasostatin, a calreticulin fragment, inhibits angio genesis and suppresses tumor growth. J Exp Med, 188, 23492356.
  • Roop DR, Krieg TM, Mehrel T, Cheng CK and Yuspa SH (1988) Transcriptional control of high molecular weight keratin gene expression in multistage mouse skin carcinogenesis. Cancer Res, 48, 32453252.
  • Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD and Murphy-Ullrich JE (1995) Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem, 270, 73047310.
  • Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P and Detmar M (1999a) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA, 96, 1488814893.
  • Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J and Detmar M (1999b) Overexpression of thrombo spondin-1 decreases angiogenesis and inhibits the growth of human squamous cell carcinomas. Am J Pathol, 155, 441452.
  • Streit M et al. (2000) Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J, 19, 32723282.
  • Toftgard R, Yuspa SH and Roop DR (1985) Keratin gene expression in mouse skin tumors and in mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res, 45, 58455850.
  • Tokunaga T et al. (1999) Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer, 79, 354359.
  • Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol, 122, 497511.
  • Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF and Bouck N (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun, 217, 326332.
  • Volpert OV, Lawler J and Bouck NP (1998) A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA, 95, 63436348.
  • Weiss RA, Eichner R and Sun TT (1984) Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kDalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol, 98, 13971406.
  • Yang Z, Kyriakides TR and Bornstein P (2000) Matricellular proteins as modulators of cell–matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell, 11, 33533364.
  • Zabrenetzky V, Harris CC, Steeg PS and Roberts DD (1994) Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer, 59, 191195.